Boehringer Ingelheim has formed a new multi-year research and drug discovery collaboration and licensing agreement with the biopharmaceutical company, Inventiva, for the development of drug to treat idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. The partnership will combine Inventiva's know-how and proprietary technologies in the field of transcriptional regulation and fibrosis with Boehringer Ingelheim's capabilities in drug discovery and clinical development of new therapeutic agents.

Boehringer Ingelheim has successfully developed Ofev (nintedanib), a small-molecule tyrosine kinase inhibitor, approved and marketed globally for the treatment of IPF in adults and will be responsible for clinical development and commercialization of potential drug candidates from the collaboration.

Inventiva will receive an upfront payment and is eligible to receive research funding, potential research, development, regulatory and commercial milestone payments of up to EUR 170 million and tiered royalties on net sales of the products resulting from the partnership.

Source: Boehringer Ingelheim